Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | CTSV | O60911 | 4/20 | 0.53 |
| ▸ | CTSL | P07711 | 4/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502844 | 0.85 | POLB (0.58) | MEN1KMT2AMAPTCTSVCTSL | |
| SCHEMBL5421861 | 0.85 | POLB (0.58) | MEN1KMT2AMAPTCTSVCTSL | |
| SCHEMBL7350875 | 0.84 | MEN1 (0.56) | MEN1KMT2AMAPTCTSVCTSL | |
| SCHEMBL3997761 | 0.84 | MEN1 (0.67) | MEN1KMT2AMAPTCTSVCTSL | |
| SCHEMBL5345734 | 0.83 | KMT2A (0.49) | MEN1KMT2AMAPTALDH1A1HPGD | |
| SCHEMBL8875982 | 0.82 | RAB9A (0.55) | MEN1KMT2AMAPTCTSVCTSL | |
| SCHEMBL7350886 | 0.82 | MEN1 (0.54) | MEN1KMT2AMAPTCTSVCTSL | |
| SCHEMBL7350879 | 0.82 | MEN1 (0.54) | MEN1KMT2AMAPTCTSVCTSL | |
| SCHEMBL9314457 | 0.81 | RAB9A (0.58) | MEN1KMT2AMAPTCTSVCTSL | |
| SCHEMBL4173572 | 0.81 | PLA2G4B (0.47) | MEN1KMT2AMAPTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791807-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | Pfizer Products Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006027684-A1 | THERAPEUTIC DIPHENYL ETHER LIGANDS | PFIZER PRODUCTS INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | MEN1 3874/4885KMT2A 2371/4885MAPT 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.